Topical vasoconstrictor - OptiNose
Latest Information Update: 11 Sep 2013
At a glance
- Originator OptiNose AS
- Developer OptiNose UK
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Rhinitis
Most Recent Events
- 11 Sep 2013 Discontinued - Phase-I for Rhinitis in United Kingdom (Intranasal)
- 21 Apr 2006 No development reported - Phase-I for Rhinitis in United Kingdom (Intranasal)
- 06 Feb 2005 Phase-I clinical trials in Rhinitis in United Kingdom (Intranasal)